In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $12.02 in the prior trading day, Zevra Therapeutics Inc (NASDAQ: ZVRA) closed at $11.7%, Down $-2.66%. In other words, the price has decreased by -$2.66 from its previous closing price. On the day, 1.25 million shares were traded. ZVRA stock price reached its highest trading level at $12.22 during the session, while it also had its lowest trading level at $11.3.
Ratios:
Our goal is to gain a better understanding of ZVRA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.93 and its Current Ratio is at 3.02. In the meantime, Its Debt-to-Equity ratio is 1.51 whereas as Long-Term Debt/Eq ratio is at 1.49.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on July 02, 2025, initiated with a Buy rating and assigned the stock a target price of $26.
On October 07, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $20.Guggenheim initiated its Buy rating on October 07, 2024, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 26 ’25 when Thompson Rahsaan sold 24,000 shares for $9.21 per share. The transaction valued at 221,004 led to the insider holds 42,666 shares of the business.
RAHSAAN THOMPSON bought 24,000 shares of ZVRA for $223,920 on Jun 26 ’25. On Mar 28 ’25, another insider, Watton Corey Michael, who serves as the Director of the company, bought 300 shares for $7.84 each. As a result, the insider paid 2,352 and bolstered with 1,800 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZVRA now has a Market Capitalization of 639751296 and an Enterprise Value of 638957824. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.76 while its Price-to-Book (P/B) ratio in mrq is 15.59. Its current Enterprise Value per Revenue stands at 15.743 whereas that against EBITDA is -9.77.
Stock Price History:
The Beta on a monthly basis for ZVRA is 1.57, which has changed by 0.72566366 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, ZVRA has reached a high of $13.16, while it has fallen to a 52-week low of $6.19. The 50-Day Moving Average of the stock is 11.95%, while the 200-Day Moving Average is calculated to be 34.55%.
Shares Statistics:
The stock has traded on average 925.48K shares per day over the past 3-months and 893210 shares per day over the last 10 days, according to various share statistics. A total of 54.68M shares are outstanding, with a floating share count of 54.03M. Insiders hold about 1.18% of the company’s shares, while institutions hold 61.25% stake in the company. Shares short for ZVRA as of 1752537600 were 4895563 with a Short Ratio of 5.29, compared to 1749772800 on 4711373. Therefore, it implies a Short% of Shares Outstanding of 4895563 and a Short% of Float of 9.0100005.
Earnings Estimates
At present, 8.0 analysts are actively evaluating the performance of Zevra Therapeutics Inc (ZVRA) in the stock market.The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.04 and low estimates of -$0.1.
Analysts are recommending an EPS of between $2.42 and -$0.34 for the fiscal current year, implying an average EPS of $1.21. EPS for the following year is $0.63, with 8.0 analysts recommending between $1.93 and -$0.01.
Revenue Estimates
8 analysts predict $22.49M in revenue for the current quarter. It ranges from a high estimate of $24.3M to a low estimate of $20.6M. As of the current estimate, Zevra Therapeutics Inc’s year-ago sales were $4.45MFor the next quarter, 8 analysts are estimating revenue of $24.32M. There is a high estimate of $26.1M for the next quarter, whereas the lowest estimate is $22.2M.
A total of 8 analysts have provided revenue estimates for ZVRA’s current fiscal year. The highest revenue estimate was $99.4M, while the lowest revenue estimate was $87M, resulting in an average revenue estimate of $93.4M. In the same quarter a year ago, actual revenue was $23.61MBased on 8 analysts’ estimates, the company’s revenue will be $162.66M in the next fiscal year. The high estimate is $232M and the low estimate is $114.6M.
